Skip to main content

Advertisement

SpringerLink
Log in

Changes in Bile Acid Profile After Laparoscopic Sleeve Gastrectomy are Associated with Improvements in Metabolic Profile and Fatty Liver Disease

  • Original Contributions
  • Published:
Obesity Surgery Aims and scope Submit manuscript

Abstract

Background

Bile acids (BA) modulate lipid and glucose metabolism in a feedback loop through production of fibroblast growth factor (FGF) 19 in the terminal ileum. Changes in BA after bariatric surgery may lead to improvements in the metabolic syndrome, including fatty liver disease. This study investigated the relationship between BA and metabolic and inflammatory profiles after laparoscopic sleeve gastrectomy (LSG).

Methods

Patients undergoing LSG had fasting blood samples taken pre-operatively and 6 months post-surgery. Liver injury was measured using cytokeratin (CK) 18 fragments. BA were measured using liquid chromatography tandem-mass spectrometry. FGF-19 was measured using enzyme-linked immunosorbent assay.

Results

The study included 18 patients (12 females), with mean age 46.3 years (SEM ± 2.9) and BMI 60.1 kg/m2 (±2.6). After 6 months, patients lost 39.8 kg (±3.1; p < 0.001). Fourteen patients (78 %) had steatosis. FGF-19 increased from median 128.1 (IQR 89.4–210.1) to 177.1 (121.8–288.9, p = 0.045) at 6 months. Although total BA did not change, primary glycine- and taurine-conjugated BA, cholic acid decreased, and secondary BA, glycine-conjugated urodeoxycholic acid increased over the study period. These changes are associated with reduction in insulin resistance, pro-inflammatory cytokines and CK-18 levels.

Conclusions

The profile of individual BA is altered after LSG. These changes occur in the presence of reductions in inflammatory cytokines and markers of liver injury. This study supports evidence from recent animal models that LSG may have an effect on fatty liver through changes in BA metabolism.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Das UN. Obesity, metabolic syndrome X, and inflammation. Nutrition. 2002;18(5):430–2.

    Article  CAS  PubMed  Google Scholar 

  2. Caiazzo R et al. Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-year controlled longitudinal study. Ann Surg. 2014;260(5):893–8. discussion 898–9.

    Article  PubMed  Google Scholar 

  3. Tran A, Gual P. Non-alcoholic steatohepatitis in morbidly obese patients. Clin Res Hepatol Gastroenterol. 2013;37(1):17–29.

    Article  PubMed  Google Scholar 

  4. Wieckowska A et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology. 2006;44(1):27–33.

    Article  CAS  PubMed  Google Scholar 

  5. Feldstein AE et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology. 2009;50(4):1072–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Hafeez S, Ahmed MH. Bariatric surgery as potential treatment for nonalcoholic fatty liver disease: a future treatment by choice or by chance? J Obes. 2013;2013:839275.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Modica S, Gadaleta RM, Moschetta A. Deciphering the nuclear bile acid receptor FXR paradigm. Nucl Recept Signal. 2010;8:e005.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Chen X et al. TGR5: a novel target for weight maintenance and glucose metabolism. Exp Diabetes Res. 2011;2011:853501.

    PubMed  PubMed Central  Google Scholar 

  9. Li Y, Jadhav K, Zhang Y. Bile acid receptors in non-alcoholic fatty liver disease. Biochem Pharmacol. 2013;86(11):1517–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Haeusler RA et al. Human insulin resistance is associated with increased plasma levels of 12alpha-hydroxylated bile acids. Diabetes. 2013;62(12):4184–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Gerhard GS et al. A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass. Diabetes Care. 2013;36(7):1859–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Jansen PL et al. Alterations of hormonally active fibroblast growth factors after Roux-en-Y gastric bypass surgery. Dig Dis. 2011;29(1):48–51.

    Article  PubMed  Google Scholar 

  13. Patti ME et al. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring). 2009;17(9):1671–7.

    Article  CAS  Google Scholar 

  14. Pournaras DJ et al. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology. 2012;153(8):3613–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Steinert RE, et al. Bile acids and gut peptide secretion after bariatric surgery: a 1-year prospective randomized pilot trial. Obesity (Silver Spring). 2013.

  16. Haluzikova D et al. Laparoscopic sleeve gastrectomy differentially affects serum concentrations of FGF-19 and FGF-21 in morbidly obese subjects. Obesity (Silver Spring). 2013;21(7):1335–42.

    Article  CAS  Google Scholar 

  17. Bechmann LP et al. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology. 2013;57(4):1394–406.

    Article  CAS  PubMed  Google Scholar 

  18. Myronovych A et al. Vertical sleeve gastrectomy reduces hepatic steatosis while increasing serum bile acids in a weight-loss-independent manner. Obesity (Silver Spring). 2014;22(2):390–400.

    Article  CAS  Google Scholar 

  19. Ryan KK et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature. 2014;509(7499):183–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Ooi CP, Loke SC. Colesevelam for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2012;12:CD009361.

    PubMed  Google Scholar 

  21. Beysen C et al. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. Diabetologia. 2012;55(2):432–42.

    Article  CAS  PubMed  Google Scholar 

  22. Chamulitrat W et al. Ursodeoxycholyl lysophosphatidylethanolamide inhibits lipoapoptosis by shifting fatty acid pools toward monosaturated and polyunsaturated fatty acids in mouse hepatocytes. Mol Pharmacol. 2013;84(5):696–709.

    Article  CAS  PubMed  Google Scholar 

  23. Xiang Z et al. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review. BMC Gastroenterol. 2013;13:140.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Owen-Smith A et al. A NICE example? Variation in provision of bariatric surgery in England. BMJ. 2013;346:f2453.

    Article  PubMed  Google Scholar 

  25. MacLaughlin HL et al. Laparoscopic sleeve gastrectomy is a novel and effective treatment for obesity in patients with chronic kidney disease. Obes Surg. 2012;22(1):119–23.

    Article  PubMed  Google Scholar 

  26. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487–95.

    Article  PubMed  Google Scholar 

  27. Tagliacozzi D et al. Quantitative analysis of bile acids in human plasma by liquid chromatography-electrospray tandem mass spectrometry: a simple and rapid one-step method. Clin Chem Lab Med. 2003;41(12):1633–41.

    Article  CAS  PubMed  Google Scholar 

  28. Brunt EM et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011;53(3):810–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Boden G. Obesity and free fatty acids. Endocrinol Metab Clin North Am. 2008;37(3):635–46. viii-ix.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Carswell KA, et al. A systematic review and meta-analysis of the effect of gastric bypass surgery on plasma lipid levels. Obes Surg, 2015.

  31. Rao SR. Inflammatory markers and bariatric surgery: a meta-analysis. Inflamm Res. 2012;61(8):789–807.

    Article  CAS  PubMed  Google Scholar 

  32. Terra X et al. Long-term changes in leptin, chemerin and ghrelin levels following different bariatric surgery procedures: Roux-en-Y gastric bypass and sleeve gastrectomy. Obes Surg. 2013;23(11):1790–8.

    Article  PubMed  Google Scholar 

  33. Dali-Youcef N et al. Metabolic inflammation: connecting obesity and insulin resistance. Ann Med. 2013;45(3):242–53.

    Article  CAS  PubMed  Google Scholar 

  34. Xu XJ et al. What distinguishes adipose tissue of severely obese humans who are insulin sensitive and resistant? Curr Opin Lipidol. 2013;24(1):49–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Diab DL et al. Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin Gastroenterol Hepatol. 2008;6(11):1249–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Kahraman A et al. Fetuin-A mRNA expression is elevated in NASH compared with NAFL patients. Clin Sci (Lond). 2013;125(8):391–400.

    Article  CAS  Google Scholar 

  37. Melissas J et al. Alterations of global gastrointestinal motility after sleeve gastrectomy: a prospective study. Ann Surg. 2013;258(6):976–82.

    Article  PubMed  Google Scholar 

  38. Pournaras DJ, le Roux CW. Are bile acids the new gut hormones? Lessons from weight loss surgery models. Endocrinology. 2013;154(7):2255–6.

    Article  CAS  PubMed  Google Scholar 

  39. Kohli R et al. A surgical model in male obese rats uncovers protective effects of bile acids post-bariatric surgery. Endocrinology. 2013;154(7):2341–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Kong LC et al. Gut microbiota after gastric bypass in human obesity: increased richness and associations of bacterial genera with adipose tissue genes. Am J Clin Nutr. 2013;98(1):16–24.

    Article  CAS  PubMed  Google Scholar 

  41. Esteve E, Ricart W, Fernandez-Real JM. Gut microbiota interactions with obesity, insulin resistance and type 2 diabetes: did gut microbiote co-evolve with insulin resistance? Curr Opin Clin Nutr Metab Care. 2011;14(5):483–90.

    Article  CAS  PubMed  Google Scholar 

  42. Monte SV et al. Reduction in endotoxemia, oxidative and inflammatory stress, and insulin resistance after Roux-en-Y gastric bypass surgery in patients with morbid obesity and type 2 diabetes mellitus. Surgery. 2012;151(4):587–93.

    Article  PubMed  Google Scholar 

  43. Damms-Machado A et al. Effects of surgical and dietary weight loss therapy for obesity on gut microbiota composition and nutrient absorption. Biomed Res Int. 2015;2015:806248.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Pathil A et al. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease. Hepatology. 2012;55(5):1369–78.

    Article  CAS  PubMed  Google Scholar 

  45. Buko VU et al. Ursodeoxycholic acid dose-dependently improves liver injury in rats fed a methionine- and choline-deficient diet. Hepatol Res. 2011;41(7):647–59.

    Article  CAS  PubMed  Google Scholar 

  46. Luo L et al. Evaluation of serum bile acid profiles as biomarkers of liver injury in rodents. Toxicol Sci. 2014;137(1):12–25.

    Article  CAS  PubMed  Google Scholar 

  47. Aranha MM et al. Bile acid levels are increased in the liver of patients with steatohepatitis. Eur J Gastroenterol Hepatol. 2008;20(6):519–25.

    Article  CAS  PubMed  Google Scholar 

  48. Myronovych A et al. The role of small heterodimer partner in nonalcoholic fatty liver disease improvement after sleeve gastrectomy in mice. Obesity (Silver Spring). 2014;22(11):2301–11.

    Article  CAS  Google Scholar 

  49. Illan-Gomez F et al. Obesity and inflammation: change in adiponectin, C-reactive protein, tumour necrosis factor-alpha and interleukin-6 after bariatric surgery. Obes Surg. 2012;22(6):950–5.

    Article  PubMed  Google Scholar 

  50. Mudaliar S et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013;145(3):574–82 e1.

    Article  CAS  PubMed  Google Scholar 

  51. Li JV et al. Metabolic surgery profoundly influences gut microbial-host metabolic cross-talk. Gut. 2011;60(9):1214–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Werling M et al. Enhanced fasting and post-prandial plasma bile acid responses after Roux-en-Y gastric bypass surgery. Scand J Gastroenterol. 2013;48(11):1257–64.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Minimally Invasive, Bariatric and Laparoscopic HPB Surgery, King’s College Hospital, London, SE5 9RS, UK

    Ajay P. Belgaumkar, Kirstin A. Carswell & Ameet G. Patel

  2. Department of Biochemistry, King’s College Hospital, London, UK

    Royce P. Vincent & Jamie Alaghband-Zadeh

  3. Institute of Liver Studies, King’s College Hospital, London, UK

    Robin D. Hughes & Ragai R. Mitry

  4. Diabetes Complications Research Centre, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Ireland

    Carel W. le Roux

Authors
  1. Ajay P. Belgaumkar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Royce P. Vincent
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kirstin A. Carswell
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robin D. Hughes
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jamie Alaghband-Zadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ragai R. Mitry
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Carel W. le Roux
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ameet G. Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ajay P. Belgaumkar.

Ethics declarations

Compliance with Ethical Standards

Informed consent was obtained from all individual participants included in the study. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Conflict of Interest

The authors declare that they have no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Belgaumkar, A.P., Vincent, R.P., Carswell, K.A. et al. Changes in Bile Acid Profile After Laparoscopic Sleeve Gastrectomy are Associated with Improvements in Metabolic Profile and Fatty Liver Disease. OBES SURG 26, 1195–1202 (2016). https://doi.org/10.1007/s11695-015-1878-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11695-015-1878-1

Keywords

Search

Navigation